Findings

What do systematic reviews say?

28 questions · 28 findings · 1 reviews

No studies found 13 · 46.4%GRADE not reported 0 · 0%Very low 5 · 17.9%Low 6 · 21.4%Moderate 4 · 14.3%High 0 · 0%

FVC (% predicted) Change from baseline · 13 people with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low

Change from baseline in 6MWT (metres) · 90 people with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Moderate

FVC (% predicted) Change from baseline · 90 people with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Moderate

Infusion reactions · 90 people with LOPD

Alglucosidase alfa showed no clear difference in infusion reactions compared with placebo (low certainty).

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
RR 1.21 [0.57, 2.61]
1 study · 90 participants
Low

Need for respiratory support · 90 people with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Use of a walking aid / wheelchair · 90 people with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

QoL (PCS in SF‐36 (measured on a scale from 0 to 100)) · 90 people with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · 90 people with LOPD

Alglucosidase alfa showed no clear difference in treatment‐related AEs compared with placebo (low certainty).

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
RR 0.94 [0.64, 1.39]
1 study · 90 participants
Low